- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Thanks to massive government efforts worldwide, we now have several approved vaccines. Aside from protecting your health, a coronavirus vaccine can help you earn some money if you invest in the right company.
As of September 2021, there are eight either fully approved vaccines or approved for emergency use by the WHO or governments worldwide. These vaccines are made by the companies:
Yes. As long as the company developing the vaccine is a publicly-traded entity, investors can back as many COVID-19 vaccine candidates as they like.
As far as stock performance goes, many have seen staggering success. Maryland-based firm NovaVax has seen its stock price rise more than 6,000% from January 2020, while Moderna has risen over 2,000%.
AstraZeneca is a British-Swedish pharmaceutical company headquartered in Cambridge, England. It partnered with Oxford University to create the Vaxzevria vaccine, which was first authorized for emergency use in the UK and Argentina in December 2020.
Sinovac Biotech is a Chinese biotechnology company headquartered in Beijing. Its vaccine, the CoronaVac, was given a conditional approval in China in February 2021.
Pfizer Inc is a US pharmaceutical company. It has partnered with German biotech company BioNTech to create and manufacture a COVID vaccine. Their vaccine is approved by the FDA for those 16 or older, and it has an emergency authorization for those who are between 12 and 15 years old.
Sinopharm Group is a Chinese pharmaceuticals company currently trialing two vaccine candidates in partnership with the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products. Both vaccines are approved for emergency use in many countries, while only one of the vaccines is approved for emergency use by the WHO.
Moderna is a Boston-based biotechnology company. The US government supported the company with almost $1 billion to accelerate the development of a coronavirus vaccine in partnership with the National Institute of Allergy and Infectious Diseases. In December 2020, FDA gave the vaccine an emergency use authorization, but now the company has filed for a full FDA approval for those 18 or older.
CanSino Biologics is a Chinese vaccine maker working in partnership with the Academy of Military Medical Sciences. Unlike many other vaccines, this one requires only one shot.
American pharmaceutical corporation Johnson & Johnson is the parent company of Janssen Vaccines & Prevention. Janssen received an emergency authorization by the FDA in February 2021.
Novavax is a US vaccine development firm headquartered in Maryland. It started Phase 3 human trials in the UK in mid-September. The Chief executive of Novavax expects an emergency use approval by the FDA in the fourth quarter of 2021.
BioNTech is a German biotechnology company. It has partnered with Chinese pharmaceutical firm Fosun Pharma and US pharmaceutical company Pfizer to trial and manufacture a vaccine candidate.
Fosun Pharma is a Chinese pharmaceutical firm. It has partnered with German biotech company BioNTech and US pharmaceutical company Pfizer to trial and manufacture a vaccine candidate.
A number of the listed companies working on a COVID-19 cure are from countries outside the US. And most US brokerages only offer access to domestic stock exchanges, like the NYSE and NASDAQ.
That said, some international companies dual-list in the US, like AstraZeneca and Sinovac Biotech. Both can be accessed on the NASDAQ.
But if you’d like to invest in any of the others, be prepared to open an international brokerage account with a platform that offers access to global markets, like Charles Schwab, Fidelity or Interactive Brokers. These brokerages can connect you to overseas exchanges, but consider the platform’s fees and exchange rates before you apply.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.